Leerink downgraded Applied Therapeutics (APLT) to Market Perform from Outperform with a price target of $1, down from $2. With growing concerns over Applied Therapeutics’ balance sheet and the likelihood that the company will need to run two additional Phase 3 studies to get govorestat across the goal line, the firm is moving to the sidelines and cutting the stock’s rating to Marker Perform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Hold Rating Issued for Applied Therapeutics Amid Strategic Alternatives and Govorestat Uncertainty
- Applied Therapeutics Announces Strategic Review and Workforce Cuts
- Applied Therapeutics explores strategic alternatives, reduces workforce by 46%
- Applied Therapeutics to request additional Type C meeting regarding govorestat
- Applied Therapeutics Reports Quarterly Financial Results